Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baize DC Injection in Preventing Recurrence After Radical Tumor Surgery
NCT06015269Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Baize DC in solid tumor, sponsored by Shanghai Cell Therapy Group. Primary endpoint: Dose-limiting toxicity at 1 month. Status: unknown.
02
Drugs
Baize DC
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06015269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015269.